Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

A New Honor for Prof. Arnon Nagler, President of the Hemato-Oncology Center at Sheba

Prof. Arnon Nagler Forbes
Prof. Arnon Nagler, the highly esteemed clinician and researcher was named among the leading hematologists in Israel according to Forbes magazine

Not unaccustomed to accolades and honors, Prof. Arnon Nagler was yet again recognized for his expertise and clinical excellence: this time by Forbes magazine, which named him one of Israel’s leading hematologists.

A pioneer of non-myeloablative and reduced intensity\toxicity allogeneic transplantations for both malignant and non-malignant tumors, Prof. Nagler has published hundreds of articles, reviews, and chapters in premier peer-reviewed journals, and has served as head of Sheba’s hematological array for the past 20 years. Notwithstanding, Prof. Nagler also maintains a senior teaching position at Tel-Aviv University, and has held prominent leadership positions in international cancer organizations throughout his extensive career.

Upon learning of this latest honor, Prof. Nagler offered the following remarks: “allogeneic transplantations and cell immunotherapy are at the cutting-edge of cancer care and constitute life-saving treatments for many patients. I am truly grateful for the privilege to dedicate my professional life towards developing these therapies.”

virtual care
Nuvo Group and Sheba Develop AI-Powered Gestational Diabetes Management Platform
A groundbreaking gestational diabetes pilot was recently completed by the two organizations, deploying Nuvo's INVU platform at Sheba’s Beyond Virtual Hospital, simplifying care for pregnant…
Read More
pain treatment for pancreatic cancer
Breakthrough Study: Radiation Therapy Effective for Pain Management in Cancer Patients
Pancreatic cancer, the 12th most common cancer worldwide, is associated with pain in approximately 75% of patients at the time of diagnosis, and as much…
Read More
arc center
News Nov 30.
Real-Time Detection of Cancerous Biomarkers With Artificial Intelligence
Lung cancer is the most common cancer and accounts for 1.76 million deaths per year worldwide. Non-small cell lung cancer (NSCLC) comprises 85% of all…
Read More